Skip to main content

Table 3 Univariate and multivariate logistic regression analyses of risk factors of any LA abnormality

From: Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists

 

Separate univariate models

Multivariate modela

Clinical variable

OR (95 % CI)

p value

OR (95 % CI)

p value

Dabigatran vs. VKA

0.32 (0.07–1.46)

0.141

0.40 (0.08–1.88)

0.245

Rivaroxaban vs. VKA

0.55 (0.19–1.62)

0.28

0.65 (0.22–1.98)

0.453

CHADS2: 2 vs. 0–1

4.40 (1.54–12.54)

0.006

4.07 (1.42–11.69)

0.009

CHADS2: ≥3 vs. 0–1

3.80 (0.89–16.16)

0.071

3.19 (0.73–13.99)

0.124

CHA2DS2-VASC: 2 vs. 0–1

1.99 (0.38–10.55)

0.419

  

CHA2DS2-VASC: 3 vs. 0–1

2.03 (0.36–11.41)

0.423

  

CHA2DS2-VASC: ≥4 vs. 0–1

6.30 (1.28–30.95)

0.023

  

HAS–BLED: 2 vs. 0–1

2.57 (0.87–7.60)

0.089

  

HAS–BLED: ≥3 vs. 0–1

3.11 (0.70–13.80)

0.135

  

Non-banded LAA vs. banded LAA

0.64 (0.21–1.99)

0.443

  

Unknown LAA vs. banded LAA

0.00 (0.00,∞)

0.99

  

Beta blocker

1.64 (0.21–12.84)

0.636

  

Calcium blocker

0.21 (0.03–1.61)

0.133

  

Dronedarone

1.49 (0.32–6.89)

0.61

  

Statin

1.24 (0.49–3.13)

0.657

  

NSAR

0.77 (0.17–3.47)

0.735

  
  1. CI confidence interval, LAA left atrial appendage, NSAR non-steroidal anti-rheumatic agents, OR odds ratio, VKA vitamin K antagonists
  2. aFinal model resulting from an all-subset variable selection based on Akaike’s Information Criterion; the medication group (dabigatran vs. VKA and rivaroxaban vs. VKA) was defined as fixed covariate, and the significant variables in column 1 were considered as possible covariates
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us